Plans and Services
- Medical
- Pharmacy
- Health and Wellness Programs
- Behavioral Health Programs
- Dental and Vision
- Health Savings and Spending Accounts
- Cost Control Strategies
- Supplemental Health Solutions
- Accidental Injury, Critical Illness, and Hospital Care (Indemnity) Insurance
Who We Serve
By Size
- Small Businesses (2-99 employees)
- Small to Midsize Businesses (100-499 employees)
- Midsize to Large Businesses (500-2,999 employees)
- Large Businesses (3,000+ employees)
By Type
- Hospitals and Health Systems
- Higher Education
- K-12 Education
- State and Local Governments
- Taft-Hartley and Federal
- Third-Party Administrators
- View all business types
International
- Health Insurance for Expats
- IGO/NGOs
- Multinational Businesses
Employer Resources
- Cigna for Employers Portal Features
- Learn more about the tools and resources you'll have access to in the Cigna for Employers online portal.
Plans and Services
Plans and Services
Who We Serve
Who We Serve
- Small Businesses (2-99 employees)
- Small to Midsize Businesses (100-499 employees)
- Midsize to Large Businesses (500-2,999 employees)
- Large Businesses (3,000+ employees)
- Hospitals and Health Systems
- Higher Education
- K-12 Education
- State and Local Governments
- Taft-Hartley and Federal
- Third-Party Administrators
- View all business types
- Health Insurance for Expats
- IGO/NGOs
- Multinational Businesses
Employer Resources
Employer Resources
Embarc Benefit Protection
Protecting customers from the high costs of breakthrough gene therapy drugs.
Building a new benefits package?
Making Gene Therapy Drugs More Accessible
The Embarc Benefit Protection® solution brings together the health services, medical management, and specialty pharmacy expertise of Cigna HealthcareSM*, eviCoreTM, Accredo®, and Express Scripts®. This solution helps shield health plans and customers from the cost of breakthrough gene therapy drugs and helps to ensure access for those who need them.
Our Embarc Benefit Protection solution includes:
LUXTURNA®(voretigene neparvovec-rzyl)
This is the first FDA-approved prescription gene therapy for people with inherited retinal disease at a cost of $850K (both eyes).1
ZOLGENSMA®(onasemnogene abeparvovec-xioi)2
A $2.1M gene therapy for children under 2 years old with spinal muscular atrophy a potentially life-threatening condition.3
The financial protection against the high cost of ZOLGENSMA applies only to children born after the Embarc Benefit Protection solution is effective for their group health plan.
ZYNTEGLO®(betibeglogene autotemcel)4
Used for a blood disorder known as beta thalassemia in patients who cannot make enough beta-globin and require regular red blood cell transfusions at a cost of $2.8M.5
For existing Embarc Benefit Protection clients with effective dates of 08/01/2022 or earlier, all members who meet the solution’s clinical and network criteria for ZYNTEGLO will be able to access the drug through Embarc Benefit Protection. For clients who join Embarc Benefit Protection after 08/01/2022, Embarc Benefit Protection for ZYNTEGLO is only applicable to members who first became eligible for coverage under the Plan on and after 08/19/2022.
SKYSONA®(elivaldogene autotemcel)
With a cost of $3M,5 this gene therapy is for patients 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD)—a rare neuro-degenerative disease that can lead to progressive, irreversible loss of neurologic function and death.
HEMGENIX®(etranacogenedezaparvovec-drlb)6
A one-time gene therapy drug with a projected cost of $3.5M7 for adults living with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
For existing Embarc Benefit Protection clients with effective dates of March 1, 2023 or earlier, all customers who meet the solution’s clinical and network criteria for HEMGENIX will be able to access the drug through Embarc Benefit Protection. For clients that join Embarc Benefit Protection after March 1, 2023, the financial protection extends only to customers who join the underlying medical coverage 30 days or more after the client is effective in Embarc Benefit Protection (i.e., late enrollees).
ROCTAVIANTM (valoctocogene roxaparvovec-rvox)8
A one-time gene therapy drug with a projected cost of $2.9M9 indicated for the treatment of adults with severe hemophilia A.
CASGEVYTM (exagamglogene autotemcel)10
LYFGENIATM (lovotibeglogene autotemcel)12
Did you know?
More Cost Control Strategies
*Offered by Cigna Health and Life Insurance Company
View Cigna Healthcare Company Names
1 Drugs.com 2024: price of LUXTURNA
2 The financial protection against the high cost of ZOLGENSMA applies only to children born after the Embarc Benefit Protection solution is effective for their group health plan.
3 Drugs.com 2023: price of ZOLGENSMA
4 For existing Embarc Benefit Protection clients with effective dates of 08/01/2022 or earlier, all members who meet the solution’s clinical and network criteria for ZYNTEGLO will be able to access the therapy through Embarc Benefit Protection. For clients who join Embarc Benefit Protection after 08/01/2022, the financial protection extends only to customers who enroll in the underlying medical coverage 30 days or more after the client is effective in Embarc Benefit Protection.
5 bluebird bio 2022: published price of ZYNTEGLO and SKYSONA from the manufacturer
6 For existing Embarc Benefit Protection clients with effective dates of 03/01/2023 or earlier, all customers who meet the solution’s clinical and network criteria for HEMGENIX will be able to access the therapy through Embarc Benefit Protection. For clients who join Embarc Benefit Protection after 03/01/2023, the financial protection extends only to customers who join the underlying medical coverage 30 days or more after the client is effective in Embarc Benefit Protection.
7 CSL Behring 2023: published price of HEMGENIX from the manufacturer
8 For existing Embarc Benefit Protection clients with effective dates of 09/01/2023 or earlier, all customers who meet the solution’s clinical and network criteria for ROCTAVIAN will be able to access the therapy through Embarc Benefit Protection. For clients who join Embarc Benefit Protection after 09/01/2023, the financial protection extends only to customers who join the underlying medical coverage 30 days or more after the client is effective in Embarc Benefit Protection.
9 BioMarin 2023: published price of ROCTAVIAN
10 For existing Embarc Benefit Protection clients with effective dates of 04/01/2024 or earlier, all customers who meet the solution’s clinical and network criteria for CASGEVY will be able to access the therapy through Embarc Benefit Protection. For clients who join Embarc Benefit Protection after 04/01/2024, the financial protection extends only to customers who join the underlying medical coverage 30 days or more after the client is effective in Embarc Benefit Protection.
11 Vertex Pharmaceuticals Inc. 2023: published price of CASGEVY
12 For existing Embarc Benefit Protection clients with effective dates of 04/01/2024 or earlier, all customers who meet the solution’s clinical and network criteria for LYFGENIA will be able to access the therapy through Embarc Benefit Protection. For clients who join Embarc Benefit Protection after 04/01/2024, the financial protection extends only to customers who join the underlying medical coverage 30 days or more after the client is effective in Embarc Benefit Protection.
13 bluebird bio 2023: published price of LYFGENIA
14 Precedence Research, Gene Therapy Market Size, Growth, Trends, Report 2023-2032, precedenceresearch.com, accessed January 29, 2024
LUXTURNA is the registered trademark of Spark Therapeutics, Inc. and ZOLGENSMA is the registered trademark of AveXis, Inc. ZYNTEGLO and SKYSONA are both registered trademarks of bluebird bio, Inc. HEMGENIX is the registered trademark of CSL Behring, L.L.C. ROCTAVIAN is a registered trademark of BioMarin. CASGEVY is a registered trademark of Vertex Pharmaceuticals Inc. LYFGENIA is a registered trademark of bluebird bio, Inc.
Product availability may vary by location and plan type and is subject to change. For costs and details contact a Cigna Healthcare representative.
All Cigna Healthcare products and services are provided exclusively by or through operating subsidiaries of The Cigna Group, including Cigna Health and Life Insurance Company (Bloomfield, CT.) (CHLIC), eviCore healthcare MSI, LLC (d/b/a/ eviCore healthcare), Express Scripts, Inc., Accredo Health Group, Inc., or their affiliates.
In Utah, all products and services are provided by Cigna Health and Life Insurance Company (Bloomfield, CT). Policy forms: OK – HP-APP-1 et al., OR – HP-POL38 02-13, TN – HP-POL43/HC-CER1V1 et al. (CHLIC); GSA-COVER, et al. (CHC-TN).
©
Some content provided under license
Let's Get Started
Thank you for your interest in Cigna Healthcare. Please provide some basic information about your company and a representative will contact you.
Thank you
Your data has been submitted.Oops!
There was a problem submitting your data, please try again later.I want to...
Audiences
Secure Member Sites
The Cigna Group Information
Disclaimer
Individual and family medical and dental insurance plans are insured by Cigna Health and Life Insurance Company (CHLIC), Cigna HealthCare of Arizona, Inc., Cigna HealthCare of Illinois, Inc., Cigna HealthCare of Georgia, Inc., Cigna HealthCare of North Carolina, Inc., Cigna HealthCare of South Carolina, Inc., and Cigna HealthCare of Texas, Inc. Group health insurance and health benefit plans are insured or administered by CHLIC, Connecticut General Life Insurance Company (CGLIC), or their affiliates (see a listing of the legal entities that insure or administer group HMO, dental HMO, and other products or services in your state). Accidental Injury, Critical Illness, and Hospital Care plans or insurance policies are distributed exclusively by or through operating subsidiaries of The Cigna Group Corporation, are administered by Cigna Health and Life Insurance Company, and are insured by either (i) Cigna Health and Life Insurance Company (Bloomfield, CT). The Cigna Healthcare name, logo, and other Cigna Healthcare marks are owned by The Cigna Group Intellectual Property, Inc.
All insurance policies and group benefit plans contain exclusions and limitations. For availability, costs and complete details of coverage, contact a licensed agent or Cigna Healthcare sales representative. This website is not intended for residents of Arizona and New Mexico.